| Date Checked | 2025-12-21 23:23:02 |
|---|
| Graham Number | (PB)nan vs (PE)0.00 |
|---|
| Over / Under Value Percentage | 0.00% vs 0.00% |
|---|
| Dividend Yield | 0.00% |
|---|
| Dividend Date | None |
|---|
| Symbol | TBIO |
|---|
| AssetType | Common Stock |
|---|
| Name | Telesis Bio Inc. |
|---|
| Description | Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutic company, develops drugs to treat diseases caused by protein or gene dysfunction. The company is headquartered in Lexington, Massachusetts. |
|---|
| CIK | 1850079 |
|---|
| Exchange | NASDAQ |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | LIFE SCIENCES |
|---|
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
|---|
| Address | 9535 WAPLES STREET, SUITE 100, SAN DIEGO, CA, US |
|---|
| FiscalYearEnd | December |
|---|
| LatestQuarter | 2023-03-31 |
|---|
| MarketCapitalization | None |
|---|
| EBITDA | -42738000 |
|---|
| PERatio | 0 |
|---|
| PEGRatio | None |
|---|
| BookValue | 1.233 |
|---|
| DividendPerShare | 0 |
|---|
| EPS | -1.57 |
|---|
| RevenuePerShareTTM | 0.952 |
|---|
| ProfitMargin | -1.65 |
|---|
| OperatingMarginTTM | -1.586 |
|---|
| ReturnOnAssetsTTM | -0.278 |
|---|
| ReturnOnEquityTTM | -0.809 |
|---|
| RevenueTTM | 28115000 |
|---|
| GrossProfitTTM | 15595000 |
|---|
| DilutedEPSTTM | -1.57 |
|---|
| QuarterlyEarningsGrowthYOY | 0 |
|---|
| QuarterlyRevenueGrowthYOY | 0.121 |
|---|
| AnalystTargetPrice | 5 |
|---|
| TrailingPE | - |
|---|
| ForwardPE | - |
|---|
| PriceToSalesRatioTTM | - |
|---|
| PriceToBookRatio | - |
|---|
| EVToRevenue | - |
|---|
| EVToEBITDA | - |
|---|
| Beta | 2.202 |
|---|
| 52WeekHigh | 3.32 |
|---|
| 52WeekLow | 1.08 |
|---|
| 50DayMovingAverage | 2.093 |
|---|
| 200DayMovingAverage | 1.896 |
|---|
| SharesOutstanding | 30000000 |
|---|
| ExDividendDate | None |
|---|
| naga | 0 |
|---|
| etoro | 0 |
|---|
| dateChecked | 2025-12-21 23:23:02 |
|---|
| fresh | 1 |
|---|